Ace inhibitors vs arbs
Pro Research Analysisby 
Searched over 200M research papers
Comparative Efficacy of ACE Inhibitors vs ARBs in Hypertension and Heart Failure
Multiple studies show that ACE inhibitors and ARBs are equally effective in lowering blood pressure and managing heart failure. Both drug classes lead to similar reductions in systolic and diastolic blood pressure, and there is no significant difference in their ability to prevent major cardiovascular events such as heart attack, stroke, or heart failure hospitalization Nawaz2024Chen2021Cutrell2023+3 MORE. This equivalence in efficacy is consistent across diverse patient populations and healthcare settings Nawaz2024Chen2021Cutrell2023+3 MORE.
Safety and Tolerability: Side Effects of ACE Inhibitors vs ARBs
While both ACE inhibitors and ARBs are effective, their side effect profiles differ. ACE inhibitors are more likely to cause cough and angioedema due to their effect on bradykinin, whereas ARBs have a lower risk of these side effects Chen2021Cutrell2023Messerli2018+2 MORE. Studies consistently report that patients on ARBs are less likely to discontinue treatment due to adverse effects, making ARBs better tolerated overall Chen2021Cutrell2023Messerli2018+2 MORE. Other side effects, such as pancreatitis and gastrointestinal bleeding, are also less common with ARBs .
Cost-Effectiveness in Heart Failure Management
From a healthcare system perspective, ACE inhibitors are generally more cost-effective than ARBs, especially in patients with severe heart failure. ACE inhibitors tend to have lower overall costs and slightly better quality-adjusted life years compared to ARBs. However, for most patients, especially those under 65 or with less severe disease, both drug classes have similar cost-effectiveness profiles .
Special Populations: Diabetes, Kidney Disease, and Insulin Sensitivity
In patients with diabetic kidney disease, both ACE inhibitors and ARBs are similarly effective at slowing disease progression, but there is limited direct comparison data for mortality benefits . Regarding insulin sensitivity, ACE inhibitors may offer a slight advantage over ARBs in improving certain measures of insulin resistance, particularly in long-term use and in patients with diabetes, though the overall clinical impact is modest .
Clinical Guidelines and Real-World Practice
Current guidelines recommend both ACE inhibitors and ARBs as first-line options for hypertension and heart failure. The choice between them often depends on individual patient tolerance and side effect profiles, with ARBs preferred for those who develop cough or angioedema on ACE inhibitors Chen2021Cutrell2023Messerli2018+2 MORE. Recent large-scale studies support the preferential use of ARBs when starting treatment due to their better safety and tolerability, without sacrificing effectiveness Chen2021Cutrell2023Messerli2018.
Use During COVID-19
Both ACE inhibitors and ARBs have been shown to be safe for use during the COVID-19 pandemic, with no increased risk of severe or fatal outcomes compared to untreated patients. Patients are advised to continue these medications unless otherwise directed by their healthcare provider .
Conclusion
ACE inhibitors and ARBs are equally effective for managing hypertension and heart failure, but ARBs have a better safety and tolerability profile, making them a preferred choice for many patients. ACE inhibitors may be more cost-effective in certain heart failure populations, but the difference is small for most patients. The choice between these medications should be individualized, considering patient-specific factors, side effect risk, and cost.
Sources and full results
Most relevant research papers on this topic